SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Strategies & Market Trends : Bill Wexler's Profits of DOOM -- Ignore unavailable to you. Want to Upgrade?


To: Bill Wexler who wrote (887)6/3/1998 12:04:00 PM
From: Alan Newman  Respond to of 4634
 
I couldn't get any ZONA to short at Schwab, so I just sold some August 30 calls for 6 1/4.

Alan



To: Bill Wexler who wrote (887)6/3/1998 12:14:00 PM
From: Hank  Respond to of 4634
 
Zona's doing a pretty good job of reversing today. Funny, but all of a sudden the bulls are very quiet on the ZONA thread.



To: Bill Wexler who wrote (887)6/3/1998 4:20:00 PM
From: lindend  Read Replies (1) | Respond to of 4634
 
Thanks for the Zona info. But what about my question about the technical quality of CYBG's products?

Also, any insights about CYBG's recent acquisition of ARCA?

Finally, have you looked at WDRY? I saw it mentioned on Roger's Short Picks Thread and looked into it. The financials are not pretty, and there's some potentially serious conflicts of interest by the primary analyst of the stock. Only problem is the large short interest and extended time to cover.



To: Bill Wexler who wrote (887)6/4/1998 8:55:00 AM
From: lindend  Read Replies (1) | Respond to of 4634
 
>Zonagen admits that Vasomax is ineffective.>

What I still don't understand is why Schering-Plough is involved with ZONA if the drug is so ineffective?